跳至主要内容
临床试验/NL-OMON20240
NL-OMON20240尚未招募不适用

ow dose iron chelation as TReatment of Oxidative damage in Sickle cell disease; TROS study

Amsterdam UMC location AMC.0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • 1.High performance liquid chromatography confirmed diagnosis of HbSS or HbSß0 geno-type.
  • 2.Aged 18-65 years
  • 3.Written informed consent

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • 1.Blood transfusion in the preceding four months
  • 2.Already using iron chelation due to iron overload
  • 3.Ferritin levels of <50 µg/L and/or transferrin saturation of < 0.20.
  • 4.LDH of < 300 U/L
  • 5.Pregnancy or the desire to get pregnant in the following 6 months
  • 6.Impaired renal function of GFR < 60 ml/min/1,73m2 (CKD-EPI).
  • 7.Known allergic reaction to deferasirox.
  • 8.Other somatic or cognitive condition disturbing adherence to study treatment

研究者

发起方
Amsterdam UMC location AMC.

相似试验